CellSource to Shift Listing to TSE Standard Market After Falling Short of Prime Criteria

CellSource Co., Ltd. ( (JP:4880) ) has provided an update.

CellSource has disclosed that, as of October 31, 2025, it no longer meets the Prime Market’s continued listing criterion for market capitalization of tradable shares, although it continues to satisfy the other Prime Market requirements. To address this and align its listing venue with its current business scale and market conditions, the board has resolved to apply to move its listing from the TSE Prime Market to the TSE Standard Market during the fiscal year ending October 2026, a segment in which it already complies with all continued listing criteria. Management argues that transitioning to the Standard Market, which still secures a certain level of governance and liquidity, is the optimal framework to avoid potential designation as a security under supervision or delisting risk, while supporting the company’s mission in regenerative medicine, maintaining investor confidence, and linking future business growth to improved profitability and long-term corporate value.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen455.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

More about CellSource Co., Ltd.

CellSource Co., Ltd. is a Japan-based company focused on the social implementation of regenerative medicine. Listed on the Tokyo Stock Exchange, the company operates within the healthcare and biotechnology sector, and emphasizes governance and liquidity standards appropriate to its business scale while seeking to strengthen profitability and enhance medium- to long-term corporate value for its shareholders and other stakeholders.

Average Trading Volume: 103,777

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.95B

Learn more about 4880 stock on TipRanks’ Stock Analysis page.